Wang Bingyi, Kong Weiqi, Lv Lixin, Wang Zhiqiang
Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Heliyon. 2024 Mar 21;10(7):e28364. doi: 10.1016/j.heliyon.2024.e28364. eCollection 2024 Apr 15.
This study examined the mechanism through which plumbagin induces ferroptosis of colon cancer cells.
CCK-8 assay was performed to examine the viability of colon cancer cells (SW480 and HCT116 cells) after they were treated with 0-, 5-, 10-, 15- and 20-μmol/L plumbagin. Colony formation assay and Transwell assay were used to examine the effects of 15-μmol/L plumbagin on the proliferation, invasive ability. The ferroptosis of SW480 and HCT116 cells and the expression of p-p53, p53 and SLC7A11 were analysed. The effects of blocking necrosis, apoptosis and ferroptosis on the anti-cancer effects of plumbagin were examined. After p53 was silenced, the effects of plumbagin on proliferation, invasion, ferroptosis and SLC7A11 expression were assessed. A tumour-bearing nude mouse model was used to examine the effects of p53 silencing and/or plumbagin on tumour growth, ferroptosis and SLC7A11 expression.
Plumbagin inhibited the proliferation of SW480 and HCT116 cells and their invasive and colony-forming abilities. It increased Fe levels but significantly decreased GSH and GPX4 levels. When ferroptosis was inhibited, the effects of plumbagin on colon cancer cells were significantly alleviated. Plumbagin promoted the expression and phosphorylation of p53 and inhibited the mRNA and protein levels of SLC7A11. Silencing of p53 counteracted the effects of plumbagin on the ferroptosis and biological behaviour of SW480 and HCT116 cells. In mouse models of colon cancer, silencing of p53 attenuated the tumour-suppressing effects of plumbagin as well as its inhibitory effects on the protein level of SLC7A11 and restored the expression of GSH and GPX4.
Plumbagin promotes ferroptosis and inhibits cell proliferation and invasion by decreasing the protein expression of SLC7A11 through p53.
本研究探讨了白花丹醌诱导结肠癌细胞铁死亡的机制。
采用CCK-8法检测0、5、10、15和20μmol/L白花丹醌处理后结肠癌细胞(SW480和HCT116细胞)的活力。采用集落形成试验和Transwell试验检测15μmol/L白花丹醌对细胞增殖、侵袭能力的影响。分析SW480和HCT116细胞的铁死亡情况以及p-p53、p53和SLC7A11的表达。检测阻断坏死、凋亡和铁死亡对白花丹醌抗癌作用的影响。沉默p53后,评估白花丹醌对细胞增殖、侵袭、铁死亡和SLC7A11表达的影响。采用荷瘤裸鼠模型检测p53沉默和/或白花丹醌对肿瘤生长、铁死亡和SLC7A11表达的影响。
白花丹醌抑制SW480和HCT116细胞的增殖、侵袭和集落形成能力。它增加了铁水平,但显著降低了谷胱甘肽(GSH)和谷胱甘肽过氧化物酶4(GPX4)水平。当铁死亡被抑制时,白花丹醌对结肠癌细胞的作用明显减轻。白花丹醌促进p53的表达和磷酸化,并抑制SLC7A11的mRNA和蛋白水平。p53沉默抵消了白花丹醌对SW480和HCT116细胞铁死亡和生物学行为的影响。在结肠癌小鼠模型中,p53沉默减弱了白花丹醌的抑瘤作用及其对SLC7A11蛋白水平的抑制作用,并恢复了GSH和GPX4的表达。
白花丹醌通过p53降低SLC7A11的蛋白表达,从而促进铁死亡并抑制细胞增殖和侵袭。